Your browser doesn't support javascript.
loading
Considerations for the clinical development of immuno-oncology agents in cancer.
Pandiella, Atanasio; Calvo, Emiliano; Moreno, Victor; Amir, Eitan; Templeton, Arnoud; Ocana, Alberto.
Affiliation
  • Pandiella A; Centro de Investigación del Cáncer, CIC-CSIC, Salamanca, Spain.
  • Calvo E; Centro de Investigación Biomédica en Red en Oncología (CIBERONC), Madrid, Spain.
  • Moreno V; START Madrid-HM Centro Integral Oncológico Clara Campal (CIOCC), Early Phase Program, HM Sanchinarro University Hospital, Madrid, Spain.
  • Amir E; START Madrid-Fundación Jiménez Díaz (FJD) Early Phase Program, Fundación Jiménez Díaz Hospital, Madrid, Spain.
  • Templeton A; Division of Medical Oncology & Hematology, Department of Medicine, Princess Margaret Cancer Centre and University of Toronto, Toronto, ON, Canada.
  • Ocana A; Department of Medical Oncology, St. Claraspital, Basel, Switzerland.
Front Immunol ; 14: 1229575, 2023.
Article in En | MEDLINE | ID: mdl-37638048
Subject(s)
Key words
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Neoplasms Type of study: Prognostic_studies Limits: Humans Language: En Journal: Front Immunol Year: 2023 Document type: Article Affiliation country: Country of publication:
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Neoplasms Type of study: Prognostic_studies Limits: Humans Language: En Journal: Front Immunol Year: 2023 Document type: Article Affiliation country: Country of publication: